Objective: To study the effect of α−cypermethrin (α−CP) on some neuropharmacological paradigms like motor coordination, pentobarbitone-induced sleeping time and pentylenetetrazole-induced (PTZ) convulsion as well as γ-aminobutyric acid (GABA) level in rat brain. Materials and Methods: Albino Wistar rats were the experimental animals. Different neuropharmacological paradigms like motor coordination (determined by rotarod), pentobarbitone-induced sleeping time and PTZ-induced convulsion were carried out following oral administration of α−CP at two dose levels i.e., 145 mg/kg (LD 50 ) and 14.5 mg/kg (1/10LD 50 ), while the level of GABA in the brain of rats was estimated by HPLC after single-dose oral administration of α−CP at 145 mg/kg. Results: α−CP induced significant motor incoordination, decreased the time of onset and increased the duration of sleeping time induced by pentobarbitone; and also decreased the time of onset and increased the duration of convulsion induced by PTZ at the dose levels of 145 mg/kg (LD 50 ) and 14.5 mg/kg (1/10 LD 50 ) respectively. Further α−CP decreased brain GABA levels in the cerebellum and in whole brain (except cerebellum) significantly at LD 50 dose level. Conclusion: A correlation between the effect of α−CP on central GABA levels and its neuropharmacological effects can be hypothesized.
Introduction
Alfa-cypermethrin (α−CP) (two of the four cis-isomers of cypermethrin), is the most potent cypermethrin and is being extensively used in agricultural farming, livestock industry and to control household ectoparasites to protect human health. Synthetic pyrethroids like cypermethrin act through GABAgated chloride channels. [1] [2] [3] But reports on its pharmacological effects and its modulation of brain GABA levels are scarce. The present study was undertaken to determine its pharmacological effects with relation to its modulation of brain GABA levels, if any.
Materials and Methods
Animals: Albino Wistar rats of either sex weighing 200 ± 10 g were used. The animals were fasted overnight with water ad libitum. The Institutional Animal Ethics Committee (IAEC) approved the experimental protocol.
Dose of α−CP: α−CP was administered orally at LD 50 4 (145 mg/kg) and 1/10 th LD 50 (14.5 mg/kg) dose levels. Motor coordination by rotarod test: Dunham and Miya [5] (1956) suggested that skeletal muscle relaxation induced by a test compound could be evaluated by testing the ability of mice or rats to remain on a rotating rod. For this purpose, groups of rats were trained to remain on the rotarod for one min. The animals were discarded and replaced if they failed to do so. Thirty animals were considered and trained on rotarod. The rats were divided into three equal groups-I, II and III comprising 10 animals each. Groups I and II received α−CP at LD 50 (145 mg/kg) and 1/10 th LD 50 (14.5 mg/kg) doses orally respectively, dissolved in DMSO (1 ml). Group III received only DMSO (1 ml) and was considered as control. One h after administration of α−CP and DMSO, all the groups including control were placed on rotarod and the number of animals falling from the rotarod during the scheduled time (1 min) were counted and the percentage was transformed into probit and compared with the control group.
Pentobarbitone-induced sleeping time: Pentobarbitone-induced sleeping time was evaluated according to the method Effect of alfa-cypermethrin on brain GABA levels of Turner (1965) . [6] Thirty animals were divided into three equal groups containing 10 animals each. Pentobarbitone (Sigma Chemicals, USA) was administered (40 mg/kg, i.p.) one h after oral administration of α−CP at 145 mg/kg and 14.5 mg/kg respectively to animals of Groups I and II and sleeping time was recorded as the period starting with loss and regaining righting reflex (Table 1 ). The control group (Group III) received DMSO and Pentobarbitone.
PTZ-induced convulsion: Again 30 animals were divided into three equal groups containing 10 animals each. PTZ (Sigma Chemicals, USA) was administered (60 mg/kg, i.p.) one h after oral administration of α−CP at 145 mg/kg and 14.5 mg/kg respectively, dissolved in DMSO, to animal of Groups I and II. The vehicle (DMSO) and PTZ were given to animals of control Group III. The onset of the induction and duration of tonicclonic convulsions were recorded [6] . Determination of GABA level in brain: Twenty rats were divided into two equal groups comprising 10 animals each. Groups I received α−CP at LD 50 (145 mg/kg) dose dissolved in DMSO (1 ml). While animals of Group II received only DMSO (1 ml) and were considered as control. After 6 h of α−CP administration, the remaining six rats including control were euthanized and brain was collected, immediately divided into two parts, cerebellum and whole brain without cerebellum, and both portions were utilized for the estimation of GABA. GABA has been recognized as a major inhibitory neurotransmitter in the central nervous system of all vertebrates. It is found in the mammalian cerebellum, corpus striatum, cerebral cortex and spinal cord. Its role in various neurological and mental disorders has been described.
Several methods for the estimation of GABA levels in biological samples, by high performance liquid chromatography (HPLC), have been published. The present procedure determined the level of GABA by HPLC-ECD following its derivatization with OPA and TBT by the modified method of Allison et al (1984) . [7] The following is the reaction:
The derivative is a time-substituted isoindole, which is a stable one.
Condition of HPLC
System: Waters (USA) 464-pulsed electrochemical Detector Column: Novapak RP-C-18 column (3. Working reagent: 0.0671 g of OPA dissolved in 50 ml methyl alcohol, to which was added 56 ml of TBT Procedure: To 500 ml of diluted brain homogenate were added 20 ml of the AVA (5-amino valeric acid) stock (internal standard) and 40 ml of GABA stock and were mixed thoroughly. Working reagent of 800 ml and 200 ml of the above mixture were added to the sample and mixed thoroughly (kept capped to contain the thiol odor). The reaction was allowed to proceed at room temperature for 6 min and 50 ml of the derivatized sample was injected and run for 15 min. The retention time (RT) of the derivative as well as the unknown sample were found to be at 4.9 min and 5.1 min respectively. The data were recorded and analysis was done by Millennium package (Waters). GABA concentration was expressed as mg/gm of wet tissue.
Statistical analysis
All the values were expressed as mean±SEM. Statistical analysis was carried out using SPSS 10.1. Statistical significance of the differences between the two means was assessed by one-way ANOVA followed by Dunnett's test. A probability level of P<0.05 was considered significant.
Results

Pharmacological test:
The percentage (of animal present in the rotarod) transformed into probit following single-dose Table 2 Effect oral administration of α−CP at 145 and 14.5 mg/kg were 1.98 ± 0.60 and 5.42 ± 0.12 compared to control animals (6.10 ± 0.150). The one-way ANOVA followed by Dunnett's test was performed, and α−CP produced ataxia significantly with both LD 50 (P<0.01) and 1/10 LD 50 (P<0.05). Table 1 shows that α− CP increased the duration of pentobarbitone-induced sleep time significantly (P<0.01) while decreased the time of onset of sleep at both dose levels. Further, α−CP increased the duration of tonic-clonic convulsion induced by PTZ significantly (P<0.01) and decreased the time of onset of convulsion significantly (P<0.05) at the dose level of 145 mg/kg but not at the 1/10 LD 50 dose (Table 2) . Brain GABA level: The concentrations of brain GABA both in the cerebellum and the rest of the brain of rats, following single-dose oral administration of α−CP at 145 mg/kg were found to be 1078 ± 91.25 and 640 ± 48.46 ppm respectively in control animals compared to 218 ± 35.21 and 172 ± 23.01 ppm respectively in experimental animals. So the brain GABA levels were decreased both in the cerebellum and the rest of the brain significantly (P<0.01) after α−CP administration.
Discussion
After 3-5 h of oral administration, the animals showed a closely defined sequence of signs of toxicity like choreoathetosis, loss of righting reflex followed by tonic-clonic convulsion. [8] The rotarod test indicates that α−CP produces motor incoordination that corroborated with the findings of Crofton and Reitter (1984) . [9] The GABA receptor complex is an important target site for Type II pyrethroids like cypermethrin. [10] [11] [12] α−CP potentiated the PTZ-induced convulsion in rats. Some GABA antagonists do not interact with the GABA binding site itself but rather with separate sites on or near the chloride channel. Such non-competitive antagonists (like PTZ) block GABA-mediated Cl-flux and therefore act as a potent convulsant. [13] The GABA level is more in the cerebellum than the rest of the brain (i.e. without cerebellum) in control rats. α−CP decreased GABA levels significantly both in the cerebellum and the rest of the brain in treated rats. The decreased GABA level might be either due to decreased synthesis or increased catabolism of GABA resulting in the inactivation of the Cl-channel leading to excitation and convulsion. α−CP increased pentobarbitone-induced sleeping time in rats. Inversely, pentobarbitone reduced the CNS excitation caused by α−CP, which corroborated with the findings of Forshaw et al (2000) . [14] Pentobarbitone potentiates GABA-induced chloride conductance and simultaneously depresses voltage activated Ca ++ currents at lower concentration, but at higher concentration, chloride conductance is increased in the absence of GABA; [15] one consequence of the inhibition of these Ca ++ channels could be the blockade of Ca ++ entry into presynaptic nerve terminals leading to inhibition of the release of excitatory neurotransmitters such as glutamate. This results in net reduction of excitatory synaptic transmission.
In conclusion it was observed that alfa-cypermethrin potentiates pentobarbitone-induced sleeping time, and PTZinduced convulsion concomitant with the decrease of GABA concentration in the brain.
